Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NVO
- Price
- 62.23
- Stock movement up
- +2.91 (4.91%)
- Company name
- Novo Nordisk A/S
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 209.63B
- Ent value
- 519.94B
- Price/Sales
- 0.66
- Price/Book
- 1.23
- Div yield
- 1.88%
- Div growth
- 20.96%
- Growth years
- 2
- FCF payout
- 12.15%
- Trailing P/E
- 2.02
- Forward P/E
- 2.87
- PEG
- 1.46
- EPS growth
- 22.55%
- 1 year return (CAGR)
- -23.20%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 1.17 |
| Dividend yield | 1.88% |
| Payout frequency | - |
| Maximum yield | 4.84% |
| Average yield | 2.23% |
| Minimum yield | 0.86% |
| Discount to avg yield | -18.70% |
| Upside potential | -15.75% |
| Yield as % of max yield | 38.80% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 1.88% |
| Current yield distribution | 70.50% |
| Yield at 100% (Min) | 0.86% |
| Yield at 90% | 0.96% |
| Yield at 80% | 1.20% |
| Yield at 50% (Median) | 2.26% |
| Yield at 20% | 3.16% |
| Yield at 10% | 3.33% |
| Yield at 0% (Max) | 4.84% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 2 years |
| CCC status | - |
| Dividend per share | 1.17 |
| Payout frequency | - |
| Ex-div date | 18 Sep 2025 |
| EPS (TTM) | 23.34 |
| EPS (1y forward) | 21.69 |
| EPS growth (5y) | 22.55% |
| EPS growth (5y forward) | 1.38% |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| NVO | S&P500 | |
| DGR MR | -46.80% | -13.74% |
| DGR TTM | 16.40% | 6.60% |
| DGR 3 years | 36.48% | 7.31% |
| DGR 5 years | 20.96% | 4.69% |
| DGR 10 years | 20.25% | 6.30% |
| DGR 15 years | 20.88% | 8.16% |
| Time since last change announced | 177 days |
| EPS growth (5y) | 22.55% |
| EPS growth (5y forward) | 1.38% |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 7.35% | 12.15% |
| Average | - | - |
| Forward | 5.39% | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2.02 |
| Price to OCF | 1.69 |
| Price to FCF | 3.34 |
| Price to EBITDA | 1.30 |
| EV to EBITDA | 3.22 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.66 |
| Price to Book | 1.23 |
| EV to Sales | 1.65 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.37B |
| EPS (TTM) | 23.34 |
| FCF per share (TTM) | 14.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 315.60B |
| Gross profit (TTM) | 258.94B |
| Operating income (TTM) | 132.66B |
| Net income (TTM) | 103.77B |
| EPS (TTM) | 23.34 |
| EPS (1y forward) | 21.69 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.05% |
| Operating margin (TTM) | 42.03% |
| Profit margin (TTM) | 32.88% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.08B |
| Net receivables | 92.37B |
| Total current assets | 181.88B |
| Goodwill | 0.00 |
| Intangible assets | 106.59B |
| Property, plant and equipment | 0.00 |
| Total assets | 512.29B |
| Accounts payable | 23.90B |
| Short/Current long term debt | 101.21B |
| Total current liabilities | 234.36B |
| Total liabilities | 342.39B |
| Shareholder's equity | 169.90B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 123.78B |
| Capital expenditures (TTM) | 61.05B |
| Free cash flow (TTM) | 62.74B |
| Dividends paid (TTM) | 7.62B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 61.08% |
| Return on Assets | 20.26% |
| Return on Invested Capital | 57.04% |
| Cash Return on Invested Capital | 34.48% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 61.44 |
| Daily high | 62.44 |
| Daily low | 61.04 |
| Daily Volume | 19.4M |
| All-time high | 146.91 |
| 1y analyst estimate | 53.22 |
| Beta | 0.35 |
| EPS (TTM) | 23.34 |
| Dividend per share | 1.17 |
| Ex-div date | 18 Sep 2025 |
| Next earnings date | 4 Feb 2026 |
Downside potential
Loading...
Downside potential data
| NVO | S&P500 | |
| Current price drop from All-time high | -57.64% | -0.89% |
| Highest price drop | -69.39% | -19.00% |
| Date of highest drop | 24 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -50.89% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
209.63B
Marketcap category
Large-cap
Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Employees
78554
Website
SEC filings
CEO
Lars Fruergaard Joergensen
Country
USA
City
Novo Alle
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page